P2Y12 inhibitors adjunctive to primary PCI therapy in STEMI: Fighting against the activated platelets

International Journal of Cardiology

Volumn 163, Issue 3, 2013, Pages 249-255

  Alexopoulos, Dimitrios ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Clopidogrel; Platelets; Prasugrel; Primary PCI; STEMI; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; ELINOGREL; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; UNCLASSIFIED DRUG; CYTOCHROME P450 2C19; MULTIDRUG RESISTANCE PROTEIN 1; PURINERGIC P2Y12 RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR BLOCKING AGENT;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; AREA UNDER THE CURVE; BINDING SITE; BLOOD CLOT LYSIS; CELL INTERACTION; CLINICAL PRACTICE; DEGRANULATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; GENETIC POLYMORPHISM; GENOTYPE; HEART HEMODYNAMICS; HEART MUSCLE REVASCULARIZATION; HEART OUTPUT; HUMAN; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MICROCIRCULATION; PERCUTANEOUS CORONARY INTERVENTION; PHENOTYPE; PLATELET REACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE METABOLISM; UNSPECIFIED SIDE EFFECT; BLEEDING; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART REINFARCTION; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; BLOOD PLATELETS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS;

EID: 84874518805     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.11.088     Document Type: Review

References (60)

1. V. Fuster, L. Badimon, M. Cohen, J.A. Ambrose, J.J. Badimon, and J. Chesebro Insights into pathogenesis of acute ischemic syndromes Circulation 77 1988 1213 1220
2. M. Gawaz, F.J. Neumann, I. Ott, A. Schiessler, and A. Schömig Platelet function in acute myocardial infarction treated with direct angioplasty Circulation 93 1996 229 237
3. B. Rocca, P. Secchiero, and G. Ciabattoni Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets Proc Natl Acad Sci U S A 99 2002 7634 7639
4. Z. Huczek, J. Kochman, and K.J. Filipiak Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention J Am Coll Cardiol 46 2005 284 290
5. Z. Huczek, K.J. Filipiak, and J. Kochman Baseline platelet reactivity in acute myocardial infarction treated with primary angioplasty - influence on myocardial reperfusion, left ventricular performance, and clinical events Am Heart J 154 2007 62 70
6. M. Frossard, I. Fuchs, and J.M. Leitner Platelet function predicts myocardial damage in patients with acute myocardial infarction Circulation 110 2004 1392 1397
7. H.K. Yip, L.T. Chang, and C.K. Sun Platelet activity is a biomarker of cardiac necrosis and predictive of untoward clinical outcomes in patients with acute myocardial infarction undergoing primary coronary stenting Circ J 70 2006 31 36
8. G. Campo, M. Valgimigli, and D. Gemmati Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY study J Am Coll Cardiol 48 2006 2178 2185
9. T. Svilaas, P.J. Vlaar, and I.C. van der Horst Thrombus aspiration during primary percutaneous coronary intervention N Engl J Med 358 2008 557 567
10. J. Silvain, J.P. Collet, and C. Nagaswami Composition of coronary thrombus in acute myocardial infarction J Am Coll Cardiol 57 2011 1359 1367
11. G. Heusch, R. Schulz, D. Baumgart, M. Haude, and R. Erbel Coronary microembolisation Prog Cardiovasc Dis 44 2001 217 230
12. N.G. Uren, T. Crake, D.C. Lefroy, R. DeSilva, G.J. Davies, and A. Maseri Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction N Engl J Med 331 1994 222 227
13. C. Kupatt, H. Habazettl, and P. Hanusch c7E3Fab reduces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen. Implications for myocardial reperfusion injury Arterioscler Thromb Vasc Biol 20 2000 2226 2232
14. T.F. Choudhri, B.L. Hoh, and H.G. Zerwes Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation J Clin Invest 102 1998 1301 1310
15. G.A. Oswald, C.C.T. Smith, D.J. Betteridge, and J.S. Yudkin Raised concentrations of glucose and adrenaline and increased in vivo platelet activation after myocardial infarction Br Heart J 59 1988 663 671
16. A. Schedel, P. Schloss, H. Kluter, and P. Bugert The dopamine agonism on ADP-stimulated platelets is mediated through D2-like but not D1-like dopamine receptors Naunyn Schmiedebergs Arch Pharmacol 378 2008 431 439
17. R. Marcucci, A.M. Gori, and R. Paniccia Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
18. G. Parodi, R. Marcucci, and R. Valenti High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI JAMA 306 2011 1215 1223
19. L. Bonello, U.S. Tantry, R. Marcucci Working Group on High On-Treatment Platelet Reactivity Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
20. T.F. Althoff, M. Fischer, E. Langer, S. Ziemer, and G. Baumann Sustained enhancement of residual platelet reactivity after coronary stenting inpatients with myocardial infarction compared to elective patients Thromb Res 125 2010 e190 e196
21. S. Matetzky, B. Shenkman, and V. Guetta Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
22. P. Osmancik, R. Jirmar, and K. Hulikova A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction Catheter Cardiovasc Interv 75 2010 158-66.24.
23. F.G. Kushner, M. Hand, and S.C. Smith Jr. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 54 2009 2205 4150
24. European Association for Percutaneous Cardiovascular Interventions W. Wijns, and P. Kolh Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J 31 2010 2501 2555
25. N. von Beckerath, D. Taubert, G. Pogatsa-Murray, E. Schomig, A. Kastrati, and A. Schomig Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial Circulation 112 2005 2946 2950
26. G. Montalescot, G. Sideris, C. Meuleman ALBION Trial Investigators A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial J Am Coll Cardiol 48 2006 931 938
27. A.A. Heestermans, J.W. van Werkum, and D. Taubert Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction Thromb Res 122 2008 776 781
28. D. Taubert, A. Kastrati, and S. Harlfinger Pharmacokinetics of clopidogrel after administration of a high loading dose Thromb Haemost 92 2004 311 316
29. M.J. McCann, K. Nice-Lepard, and R.C. Rogers Dorsal medullary injection of atrial natriuretic factor (ANF) excites vagal efferents and inhibits gastric motility Brain Res 549 1991 247 252
30. T. Simon, C. Verstuyft, and M. Mary-Krause Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
31. G. Dangas, R. Mehran, G. Guagliumi HORIZONS-AMI Trial Investigators Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial J Am Coll Cardiol 54 2009 1438 1446
32. S.R. Mehta, J.F. Tanguay, J.W. Eikelboom CURRENT-OASIS 7 trial investigators Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial Lancet 376 9748 2010 1233 1243
33. C.U. Choi, S.W. Rha, and D.J. Oh Standard versus high loading doses of clopidogrel in Asian ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the Korea Acute Myocardial Infarction Registry Am Heart J 161 2011 373-382.e1-3.
34. W. Hochholzer, D. Trenk, and D. Frundi Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention Circulation 111 2005 2560 2564
35. P.A. Davlouros, A. Arseniou, and G. Hahalis Timing of clopidogrel loading before percutaneous coronary intervention in clopidogrel-naive patients with stable or unstable angina: a comparison of two strategies Am Heart J 158 2009 585 591
36. D. Alexopoulos Clopidogrel pretreatment in PCI: absolute requirement or obsolete myth? Int J Cardiol 146 2011 305 310
37. P.J. Vlaar, T. Svilaas, and K. Damman Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review Circulation 118 2008 1828 1836
38. E.I. Lev, R. Kornowski, and H. Vaknin-Assa Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction Am J Cardiol 101 2008 435 439
39. D.M. Larson, S. Duval, and S.S. Sharkey Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention Am Heart J 160 2010 202 207
40. U. Zeymer, H.R. Arntz, H. Darius, K. Huber, and J. Senges Efficacy and safety of clopidogrel 600 mg administered pre-hospitally to improve primary percutaneous coronary intervention in patients with acute myocardial infarction (CIPAMI): study rationale and design Cardiology 108 2007 265 272
41. L. Wallentin, C. Varenhorst, and S. James Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Eur Heart J 29 2008 21 30
42. S.D. Wiviott, D. Trenk, A.L. Frelinger for the PRINCIPLE-TIMI 44 Investigators Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial Circulation 116 2007 2923 2932
43. D. Alexopoulos, G. Dimitropoulos, and P. Davlouros Prasugrel overcomes high on-clopidogrel platelet reactivity post stenting more effectively than high dose (150 mg) clopidogrel: the importance of CYP2C19*2 genotyping J Am Coll Cardiol Intv 4 2011 403 410
44. D.J. Angiolillo, J.F. Saucedo, R. Deraad for the SWAP Investigators Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study J Am Coll Cardiol 56 2010 1017 1023
45. S.D. Wiviott, E. Braunwald, C.H. McCabe TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
46. Prasugrel prescribing information. Center for drug evaluation and research www.accessdata.fda.gov/drugsatfda-docs/label/2009/022307s000lbl.pdf Access date 23/12/2010.
47. G. Montalescot, S.D. Wiviott, and E. Braunwald Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITONTIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
48. C.P. Cannon, S. Husted, and R.A. Harrington Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial J Am Coll Cardiol 50 2007 1844 1851
49. P.A. Gurbel, K.P. Bliden, and K. Butler Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
50. P.A. Gurbel, K.P. Bliden, and K. Butler Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study Circulation 121 2010 1188 1199
51. P.G. Steg, S. James, R.A. Harrington for the PLATO Study Group Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis Circulation 122 2010 2131 2141
52. Authors/Task Force Members C.W. Hamm, and J.P. Bassand ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J Sep 21 2011 [Epub ahead of print]
53. R.A. Harrington, G.W. Stone, and S. McNulty Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2009 2318 2329
54. D.L. Bhatt, A.M. Lincoff, C.M. Gibson CHAMPION PLATFORM Investigators Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2009 2330 2341
55. J.S. Berger, M.T. Roe, and C.M. Gibson Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial Am Heart J 158 2009 998 1004
56. A. Bellemain-Appaix, D. Brieger, and F. Beygui New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis J Am Coll Cardiol 56 2010 1542 1551
57. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome P450 genetic polymorphisms and the response to prasugrel relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
58. L. Wallentin, S. James, R.F. Storey PLATO investigators Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
59. W.J. Rogers, J.G. Canto, H.V. Barron, J.A. Boscarino, D.A. Shoultz, and N.R. Every Treatment and outcome of myocardial infarction in hospitals with and without invasive capability. Investigators in the National Registry of Myocardial Infarction J Am Coll Cardiol 35 2000 371 379
60. M. O'Donoghue, E.M. Antman, and E. Braunwald The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis J Am Coll Cardiol 54 2009 678 685